Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
AbbVie is conducting a Phase 3 clinical trial titled ‘A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine With an Open-Label Extension.’ This study aims to assess the safety and effectiveness of ubrogepant in treating menstrual migraines, which are migraines occurring around the menstrual period in women.
The study tests ubrogepant, an investigational drug intended for the short-term prevention of menstrual migraines. Participants will receive either ubrogepant or a placebo. The treatment involves taking oral tablets for seven consecutive days, starting three days before the expected onset of menses.
The study follows a randomized, sequential intervention model with quadruple masking, involving participants, care providers, investigators, and outcomes assessors. The primary purpose is treatment-focused.
Key dates for the study include a start date of September 10, 2024, with the last update submitted on June 25, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results.
This clinical update could influence AbbVie’s stock performance and investor sentiment, as positive results may enhance the company’s position in the pharmaceutical market, particularly in the migraine treatment sector. Competitors in the industry will be closely monitoring these developments.
The study is ongoing, with further details available on the ClinicalTrials portal.